Novartis History: The Swiss Pharmaceutical Merger

Novartis AG

PharmaceuticalsFounded 1996

Reviewed by Swet Parvadiya

Last reviewed: September 12, 2026

Market Data Current As Of: September 12, 2026

Related Competitor Intelligence

Compare market positioning with top industry peers

Competitor

Explore Novartis

Core profile pages, annual revenue records, and related research hubs for this company.

Founders

Daniel Vasella

Novartis possesses arguably the most historic, entrenched founding story in the entire global pharmaceutical industry, representing the 1996 mega-merger of two ancient, competitive Swiss chemical dynasties whose origins date back to the 18th-century dye industry in Basel. The modern corporate entity was created in 1996 through the historic, shocking $27 billion mega-merger of Ciba-Geigy and Sandoz (which, at the time, was the largest corporate merger in global history). The deepest foundational roots trace back to 1758, when Johann Rudolf Geigy-Gemuseus began trading specialized chemicals and dyes in Basel, Switzerland (forming Geigy). A century later, in 1859, a brilliant chemist named Alexander Clavel established a factory in Basel to manufacture advanced synthetic fuchsine dye (forming Ciba). In 1970, these two local rivals merged to form the Ciba-Geigy conglomerate. The other pillar, Sandoz, was founded in 1886 by Dr. Alfred Kern and Edouard Sandoz, also in Basel. Like their rivals, they started by heavily manufacturing complex synthetic dyes for the textile industry. However, the world-changing pivot for all these Swiss dye companies occurred in the late 19th and early 20th centuries. They discovered a 'eureka' moment: the complex organic chemistry required to synthesize vibrant fabric dyes was identical to the complex chemistry required to synthesize effective pharmaceutical drugs. By executing the 1996 merger, the newly formed Novartis (derived from the Latin 'novae artes,' meaning new skills) consolidated centuries of intertwined, secretive Swiss chemical expertise, establishing the dominant bedrock of the modern global pharmaceutical industry.

Markus U. Diethelm

Markus U. Diethelm is a Swiss business executive who served as the CEO of Sandoz from 1991 to 1996 and as the first Chairman of the Board of Novartis from 1996 to 1999. He was the primary architect of the 1996 merger between Sandoz and Ciba-Geigy, a transaction that created Novartis and reshaped the global pharmaceutical industry. Diethelm's career at Sandoz spanned over three decades, during which he held various leadership positions in finance and operations. His leadership style was characterized by a focus on financial discipline and strategic long-term planning, qualities that were essential in navigating the complex integration of the two companies. After stepping down as Chairman of Novartis in 1999, Diethelm remained active in the business community, serving on the boards of several major Swiss corporations. He is widely respected in Switzerland for his role in creating a global pharmaceutical leader and for his commitment to maintaining the company's headquarters in Basel.

Key Milestones

1859

Founding of Ciba

Alexander Clavel and Alfred Kern founded a chemical dye works in Basel, Switzerland, to produce fuchsine, marking the earliest origin of the Ciba-Geigy half of the Novartis merger.

1886

Founding of Sandoz

Edouard Naville founded Sandoz in Basel to manufacture tartaric acid, establishing the second half of the corporate lineage that would eventually merge to form Novartis.

1996

Merger of Ciba-Geigy and Sandoz

The $30 billion merger of Ciba-Geigy and Sandoz was completed, creating Novartis AG as one of the world's largest pharmaceutical and chemical conglomerates.

2006

Acquisition of Chiron Corporation

Novartis acquired the US biotechnology company Chiron Corporation for $5.1 billion, significantly expanding its vaccine and oncology franchises.

2010

Acquisition of Alcon

Novartis completed the acquisition of the remaining stake in Alcon, the world's largest eye care company, for approximately $28 billion, creating a dominant position in ophthalmology.

2015

DOJ Settlement

Novartis agreed to pay $390 million to settle US Department of Justice allegations regarding off-label marketing and kickbacks, a significant legal and financial milestone.

2018

Vas Narasimhan Appointed CEO

Vas Narasimhan became CEO at age 41, one of the youngest leaders of a major pharmaceutical company, initiating a strategic review that would eventually lead to the Sandoz spin-off.

2023

Acquisition of Chinook Therapeutics

Novartis acquired Chinook Therapeutics for $3.2 billion upfront plus $300 million in milestones, securing late-stage assets for rare kidney diseases.

2023

Spin-off of Sandoz

On October 4, 2023, Novartis completed the 100% spin-off of its Sandoz generics division, transforming into a pure-play innovative medicines company.

2024

Acquisition of MorphoSys

Novartis acquired the German biotechnology company MorphoSys for $2.9 billion ($2.9 billion), strengthening its oncology pipeline with the anti-myelofibrosis drug pelabresib.

2025

FY2025 Financial Results

Novartis reported $54.5 billion in net sales for FY2025, with operating income reaching $17.644 billion and free cash flow at $17.596 billion, demonstrating strong performance post-Sandoz spin-off.

2025

Entresto Generic Entry

Entresto faced US generic entry in Q3 2025, resulting in a 43% quarterly sales decline in Q4 and marking the beginning of the end for the company's largest cardiovascular franchise.

Major Acquisitions

MorphoSys AG

2024

Novartis acquired MorphoSys for $2.9 billion to strengthen its oncology pipeline, specifically acquiring the anti-myelofibrosis drug pelabresib and the CD38 antibody MOR202.

Chinook Therapeutics

2023

Novartis acquired Chinook for $3.5 billion ($3.2B upfront + $300M milestones) to secure late-stage assets for rare kidney diseases, including atrasentan for IgA nephropathy.

The Medicines Company

2020

Novartis acquired The Medicines Company for $9.7 billion primarily to gain control of the cholesterol-lowering drug inclisiran, a small interfering RNA (siRNA) therapy.

Advanced Accelerator Applications

2018

Novartis acquired Advanced Accelerator Applications for $3.9 billion to establish a foothold in the emerging field of radioligand therapy for cancer.

Chiron Corporation

2006

Novartis acquired the remaining stake in Chiron Corporation for $5.1 billion to gain full control of its vaccine and oncology businesses.

Novartis Company History FAQ

What are the defining historical milestones for Novartis AG?

Since its establishment in 1996, Novartis AG expanded from an early-stage venture into a recognized leader in Pharmaceuticals, Innovative Medicines, Oncology, Immunology, Neuroscience, and Cardiovascular Medicines, overcoming key market challenges.

What major strategic pivots shaped Novartis AG's evolution?

Over its history, Novartis AG executed decisive strategic pivots toward scalable monetization and digital distribution, securing its current market leadership.

How has Novartis AG adapted to recent industry disruptions?

By continually modernizing operations and embracing workflow automation, Novartis AG maintains resilience through changing technological and economic cycles.

Founders

Daniel Vasella

Markus U. Diethelm

Key Milestones

1859

Founding of Ciba

Alexander Clavel and Alfred Kern founded a chemical dye works in Basel, Switzerland, to produce fuchsine, marking the earliest origin of the Ciba-Geigy half of the Novartis merger.

1886

Founding of Sandoz

Edouard Naville founded Sandoz in Basel to manufacture tartaric acid, establishing the second half of the corporate lineage that would eventually merge to form Novartis.

1996

Merger of Ciba-Geigy and Sandoz

The $30 billion merger of Ciba-Geigy and Sandoz was completed, creating Novartis AG as one of the world's largest pharmaceutical and chemical conglomerates.

2006

Acquisition of Chiron Corporation

Novartis acquired the US biotechnology company Chiron Corporation for $5.1 billion, significantly expanding its vaccine and oncology franchises.

2010

Acquisition of Alcon

Novartis completed the acquisition of the remaining stake in Alcon, the world's largest eye care company, for approximately $28 billion, creating a dominant position in ophthalmology.

2015

DOJ Settlement

Novartis agreed to pay $390 million to settle US Department of Justice allegations regarding off-label marketing and kickbacks, a significant legal and financial milestone.

2018

Vas Narasimhan Appointed CEO

Vas Narasimhan became CEO at age 41, one of the youngest leaders of a major pharmaceutical company, initiating a strategic review that would eventually lead to the Sandoz spin-off.

2023

Acquisition of Chinook Therapeutics

Novartis acquired Chinook Therapeutics for $3.2 billion upfront plus $300 million in milestones, securing late-stage assets for rare kidney diseases.

2023

Spin-off of Sandoz

On October 4, 2023, Novartis completed the 100% spin-off of its Sandoz generics division, transforming into a pure-play innovative medicines company.

2024

Acquisition of MorphoSys

Novartis acquired the German biotechnology company MorphoSys for $2.9 billion ($2.9 billion), strengthening its oncology pipeline with the anti-myelofibrosis drug pelabresib.

2025

FY2025 Financial Results

Novartis reported $54.5 billion in net sales for FY2025, with operating income reaching $17.644 billion and free cash flow at $17.596 billion, demonstrating strong performance post-Sandoz spin-off.

2025

Entresto Generic Entry

Entresto faced US generic entry in Q3 2025, resulting in a 43% quarterly sales decline in Q4 and marking the beginning of the end for the company's largest cardiovascular franchise.

Major Acquisitions

MorphoSys AG

2024

Novartis acquired MorphoSys for $2.9 billion to strengthen its oncology pipeline, specifically acquiring the anti-myelofibrosis drug pelabresib and the CD38 antibody MOR202.

Chinook Therapeutics

2023

Novartis acquired Chinook for $3.5 billion ($3.2B upfront + $300M milestones) to secure late-stage assets for rare kidney diseases, including atrasentan for IgA nephropathy.

The Medicines Company

2020

Novartis acquired The Medicines Company for $9.7 billion primarily to gain control of the cholesterol-lowering drug inclisiran, a small interfering RNA (siRNA) therapy.

Advanced Accelerator Applications

2018

Novartis acquired Advanced Accelerator Applications for $3.9 billion to establish a foothold in the emerging field of radioligand therapy for cancer.

Chiron Corporation

2006

Novartis acquired the remaining stake in Chiron Corporation for $5.1 billion to gain full control of its vaccine and oncology businesses.

Novartis Company History FAQ

What are the defining historical milestones for Novartis AG?

What major strategic pivots shaped Novartis AG's evolution?

Over its history, Novartis AG executed decisive strategic pivots toward scalable monetization and digital distribution, securing its current market leadership.

How has Novartis AG adapted to recent industry disruptions?

By continually modernizing operations and embracing workflow automation, Novartis AG maintains resilience through changing technological and economic cycles.

Related Competitor Intelligence

Eli Lilly and Company

Novo Nordisk A/S

Bausch Health Companies Inc.

Pfizer

Roche

Johnson And Johnson

Founding Story

Founders

Daniel Vasella

Markus U. Diethelm

Key Milestones

Founding of Ciba

Founding of Sandoz

Merger of Ciba-Geigy and Sandoz

Acquisition of Chiron Corporation

Acquisition of Alcon

DOJ Settlement

Vas Narasimhan Appointed CEO

Acquisition of Chinook Therapeutics

Spin-off of Sandoz

Acquisition of MorphoSys

FY2025 Financial Results

Entresto Generic Entry

Major Acquisitions

MorphoSys AG

Chinook Therapeutics

The Medicines Company

Advanced Accelerator Applications

Chiron Corporation

Novartis Company History FAQ

What are the defining historical milestones for Novartis AG?

What major strategic pivots shaped Novartis AG's evolution?

How has Novartis AG adapted to recent industry disruptions?

Related Companies

Compare Novartis AG History With Competitors

Related Competitor Intelligence

Eli Lilly and Company

Novo Nordisk A/S

Bausch Health Companies Inc.

Pfizer

Roche

Johnson And Johnson

Founding Story

Founders

Daniel Vasella

Markus U. Diethelm

Key Milestones

Founding of Ciba

Founding of Sandoz

Merger of Ciba-Geigy and Sandoz

Acquisition of Chiron Corporation

Acquisition of Alcon

DOJ Settlement

Vas Narasimhan Appointed CEO

Acquisition of Chinook Therapeutics

Spin-off of Sandoz

Acquisition of MorphoSys

FY2025 Financial Results

Entresto Generic Entry

Major Acquisitions

MorphoSys AG

Chinook Therapeutics

The Medicines Company

Advanced Accelerator Applications

Chiron Corporation

Novartis Company History FAQ

What are the defining historical milestones for Novartis AG?

What major strategic pivots shaped Novartis AG's evolution?

How has Novartis AG adapted to recent industry disruptions?

Related Companies

Compare Novartis AG History With Competitors